Thomas Clozel talks quickly. Very quickly. At times his thoughts seem to be generated faster than conversational language can organise them, with a new idea arriving before the previous one has been serialised.
It's a fitting trait for a man who, as CEO and co-founder of the AI biology company Owkin, has spent years trying…
The AI-drug-discovery sector in 2026 has split into two camps. One camp wants to design new molecules from first principles. The other wants to make existing pharma R&D faster, cheaper and less likely to fail. The first camp gets the magazine covers. The second camp is closer to a working business.
Owkin sits firmly in…



